Aclaris Therapeutics Key Executives
This section highlights Aclaris Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Aclaris Therapeutics
(Showing 0 of )
Aclaris Therapeutics Earnings
This section highlights Aclaris Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2024 | 2024-05-07 | $-0.28 | $-0.24 |
| Read Transcript | Q1 | 2023 | 2023-05-08 | $-0.44 | $-0.42 |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
$1.34
Stock Price
$145.10M
Market Cap
64
Employees
Wayne, PA
Location
Financial Statements
Access annual & quarterly financial statements for Aclaris Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $18.72M | $31.25M | $29.75M | $6.76M | $6.48M |
| Cost of Revenue | $2.79M | $18.08M | $11.96M | $4.71M | $5.13M |
| Gross Profit | $15.93M | $13.17M | $17.79M | $2.05M | $1.35M |
| Gross Profit Ratio | 85.09% | 42.14% | 59.80% | 30.29% | 20.81% |
| Research and Development Expenses | $33.59M | $98.38M | $77.81M | $43.81M | $31.73M |
| General and Administrative Expenses | $22.20M | $31.10M | $25.13M | $23.62M | $20.53M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $283.00K |
| Selling General and Administrative Expenses | $22.20M | $31.10M | $25.13M | $23.62M | $20.53M |
| Other Expenses | $102.07M | $-18.96M | $2.95M | $-1.14M | $-424.00K |
| Operating Expenses | $157.86M | $110.53M | $102.95M | $67.43M | $52.26M |
| Cost and Expenses | $160.65M | $128.61M | $114.91M | $72.14M | $57.39M |
| Interest Income | $7.95M | $- | $- | $- | $- |
| Interest Expense | $- | $- | $4.70M | $- | $- |
| Depreciation and Amortization | $807.00K | $863.00K | $797.00K | $923.00K | $1.32M |
| EBITDA | $-51.72M | $-117.56M | $-84.36M | $-65.06M | $-48.20M |
| EBITDA Ratio | -276.28% | -376.22% | -283.53% | -962.28% | -743.52% |
| Operating Income | $-141.93M | $-97.36M | $-85.15M | $-65.38M | $-50.91M |
| Operating Income Ratio | -758.18% | -311.55% | -286.21% | -967.08% | -785.44% |
| Total Other Income Expenses Net | $9.87M | $8.51M | $2.95M | $-1.14M | $-424.00K |
| Income Before Tax | $-132.06M | $-88.85M | $-86.91M | $-90.86M | $-51.34M |
| Income Before Tax Ratio | -705.48% | -284.32% | -292.11% | -1343.96% | -791.98% |
| Income Tax Expense | $- | $-367.00K | $1.75M | $23.42M | $-182.00K |
| Net Income | $-132.06M | $-88.48M | $-88.66M | $-114.28M | $-51.15M |
| Net Income Ratio | -705.48% | -283.15% | -298.00% | -1690.30% | -789.17% |
| EPS | $-1.71 | $-1.27 | $-1.36 | $-2.01 | $-1.20 |
| EPS Diluted | $-1.71 | $-1.27 | $-1.36 | $-2.01 | $-1.20 |
| Weighted Average Shares Outstanding | 77.30M | 69.81M | 65.21M | 56.73M | 42.54M |
| Weighted Average Shares Outstanding Diluted | 77.30M | 69.81M | 65.21M | 56.73M | 42.54M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.21M | $4.35M | $2.77M | $2.40M | $17.57M | $9.28M | $1.87M | $2.53M | $7.75M | $19.02M | $1.53M | $1.45M | $1.50M | $1.66M | $1.82M | $1.78M | $1.58M | $1.45M | $2.05M | $1.41M |
| Cost of Revenue | $9.30M | $2.41M | $1.91M | $1.84M | $6.43M | $848.00K | $1.59M | $1.87M | $1.51M | $8.22M | $1.07M | $1.16M | $1.15M | $1.10M | $1.26M | $1.20M | $1.29M | $1.19M | $1.39M | $1.27M |
| Gross Profit | $-90.00K | $1.94M | $857.00K | $558.00K | $11.14M | $8.43M | $277.00K | $659.00K | $6.24M | $10.79M | $460.00K | $298.00K | $352.00K | $560.00K | $561.00K | $575.00K | $294.00K | $260.00K | $657.00K | $138.00K |
| Gross Profit Ratio | -0.98% | 44.59% | 30.98% | 23.27% | 63.41% | 90.86% | 14.82% | 26.07% | 80.47% | 56.76% | 30.10% | 20.51% | 23.45% | 33.76% | 30.76% | 32.36% | 18.61% | 17.94% | 32.11% | 9.81% |
| Research and Development Expenses | $9.03M | $5.96M | $8.76M | $9.85M | $26.65M | $23.88M | $25.27M | $22.59M | $21.07M | $23.66M | $18.78M | $14.31M | $14.10M | $13.98M | $7.90M | $7.84M | $8.96M | $6.87M | $6.47M | $9.44M |
| General and Administrative Expenses | $4.95M | $5.65M | $4.75M | $6.84M | $8.21M | $7.09M | $8.32M | $8.79M | $7.15M | $5.81M | $6.08M | $6.10M | $6.94M | $5.98M | $5.87M | $4.83M | $4.90M | $3.86M | $5.57M | $6.20M |
| Selling and Marketing Expenses | $- | $- | $-100.00K | $-2.50M | $-4.92M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $27.00K | $257.00K |
| Selling General and Administrative Expenses | $4.95M | $5.65M | $4.65M | $4.34M | $8.21M | $7.09M | $8.32M | $8.79M | $7.15M | $5.81M | $6.08M | $6.10M | $6.94M | $5.98M | $5.87M | $4.83M | $4.90M | $3.86M | $5.57M | $6.20M |
| Other Expenses | $85.61M | $800.00K | $1.87M | $1.99M | $2.19M | $9.04M | $2.25M | $1.76M | $1.44M | $922.00K | $462.00K | $118.00K | $89.00K | $-851.00K | $-155.00K | $-225.00K | $-219.00K | $-194.00K | $-189.00K | $178.00K |
| Operating Expenses | $99.58M | $12.41M | $13.41M | $14.19M | $34.86M | $40.01M | $33.59M | $31.38M | $28.22M | $29.47M | $24.85M | $20.41M | $21.05M | $19.95M | $13.77M | $12.66M | $13.85M | $10.72M | $12.04M | $15.64M |
| Cost and Expenses | $108.89M | $14.82M | $15.32M | $16.03M | $41.29M | $40.86M | $35.18M | $33.25M | $29.73M | $37.69M | $25.92M | $21.56M | $22.19M | $21.05M | $15.03M | $13.87M | $15.14M | $11.91M | $13.43M | $16.91M |
| Interest Income | $5.96M | $1.99M | $- | $- | $- | $2.32M | $- | $- | $- | $922.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $7.95M | $- | $- | $- | $- | $- | $- | $- | $6.91M | $2.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $143.00K | $179.00K | $200.00K | $243.00K | $228.00K | $219.00K | $218.00K | $198.00K | $190.00K | $193.00K | $206.00K | $208.00K | $197.00K | $191.00K | $247.00K | $288.00K | $-449.00K | $591.00K | $606.00K | $576.00K |
| EBITDA | $-13.93M | $-9.49M | $-12.61M | $-15.99M | $-23.59M | $-29.04M | $-31.82M | $-29.92M | $-27.45M | $-18.67M | $-24.39M | $-18.91M | $-20.61M | $-19.35M | $-13.16M | $-12.01M | $-13.56M | $-9.55M | $-10.78M | $-13.46M |
| EBITDA Ratio | -151.20% | -218.41% | -455.97% | -666.72% | -134.26% | -312.89% | -1702.25% | -1183.47% | -353.99% | -98.16% | -1596.07% | -1301.24% | -1373.22% | -1166.24% | -721.44% | -675.80% | -858.23% | -658.94% | -526.64% | -956.86% |
| Operating Income | $-99.67M | $-10.47M | $-12.55M | $-13.63M | $-4.05M | $-31.58M | $-31.82M | $-30.72M | $-21.98M | $-18.67M | $-24.39M | $-20.11M | $-22.89M | $-20.30M | $-18.01M | $-28.53M | $-13.56M | $-10.46M | $-11.38M | $-15.51M |
| Operating Income Ratio | -1082.13% | -240.93% | -453.87% | -568.43% | -23.03% | -340.20% | -1702.25% | -1215.11% | -283.49% | -98.19% | -1596.47% | -1383.83% | -1525.18% | -1223.33% | -987.17% | -1605.46% | -858.23% | -722.22% | -556.26% | -1102.06% |
| Total Other Income Expenses Net | $3.12M | $2.88M | $1.87M | $-3.31M | $2.19M | $2.32M | $2.25M | $1.76M | $-5.66M | $922.00K | $462.00K | $118.00K | $89.00K | $-851.00K | $-155.00K | $-225.00K | $-219.00K | $-194.00K | $-189.00K | $178.00K |
| Income Before Tax | $-96.55M | $-7.59M | $-10.99M | $-16.94M | $-1.86M | $-29.26M | $-29.57M | $-28.16M | $-27.64M | $-19.95M | $-20.53M | $-18.79M | $-22.80M | $-21.15M | $-18.16M | $-28.75M | $-13.78M | $-10.66M | $-11.57M | $-15.33M |
| Income Before Tax Ratio | -1048.22% | -174.55% | -397.18% | -706.46% | -10.57% | -315.24% | -1582.08% | -1113.92% | -356.44% | -104.91% | -1343.72% | -1293.12% | -1519.25% | -1274.62% | -995.67% | -1618.12% | -872.09% | -735.61% | -565.49% | -1089.41% |
| Income Tax Expense | $- | $- | $- | $199.72K | $-367.00K | $-219.00K | $-1.50M | $-1.76M | $5.66M | $1.28M | $-3.86M | $-1.32M | $2.00M | $900.00K | $4.80M | $16.44M | $-182.00K | $-591.00K | $27.00K | $-318.00K |
| Net Income | $-96.55M | $-7.59M | $-10.99M | $-16.94M | $-1.49M | $-29.26M | $-29.57M | $-26.40M | $-33.29M | $-21.23M | $-16.67M | $-17.47M | $-22.80M | $-21.15M | $-18.16M | $-28.75M | $-13.17M | $-10.66M | $-11.60M | $-15.59M |
| Net Income Ratio | -1048.22% | -174.55% | -397.18% | -706.46% | -8.49% | -315.24% | -1582.08% | -1044.38% | -429.40% | -111.63% | -1090.97% | -1202.41% | -1519.25% | -1274.62% | -995.67% | -1618.12% | -833.73% | -735.61% | -566.81% | -1107.75% |
| EPS | $-1.25 | $-0.11 | $-0.15 | $-0.24 | $-0.02 | $-0.41 | $-0.42 | $-0.39 | $-0.50 | $-0.32 | $-0.25 | $-0.28 | $-0.37 | $-0.35 | $-0.34 | $-0.57 | $-0.30 | $-0.25 | $-0.28 | $-0.37 |
| EPS Diluted | $-1.25 | $-0.11 | $-0.15 | $-0.24 | $-0.02 | $-0.41 | $-0.42 | $-0.39 | $-0.50 | $-0.32 | $-0.25 | $-0.28 | $-0.37 | $-0.35 | $-0.34 | $-0.57 | $-0.30 | $-0.25 | $-0.28 | $-0.37 |
| Weighted Average Shares Outstanding | 77.30M | 71.38M | 71.29M | 71.07M | 70.87M | 70.81M | 70.63M | 66.87M | 66.69M | 66.68M | 65.99M | 61.43M | 61.23M | 61.22M | 53.97M | 50.34M | 43.59M | 42.80M | 42.13M | 41.62M |
| Weighted Average Shares Outstanding Diluted | 77.30M | 71.38M | 71.29M | 71.07M | 70.87M | 70.81M | 70.63M | 66.87M | 66.69M | 66.68M | 65.99M | 61.43M | 61.23M | 61.22M | 53.97M | 50.34M | 43.59M | 42.80M | 42.13M | 41.62M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $24.57M | $39.88M | $45.28M | $27.35M | $54.13M |
| Short Term Investments | $89.02M | $79.23M | $172.29M | $164.06M | $32.07M |
| Cash and Short Term Investments | $113.59M | $119.11M | $229.81M | $225.66M | $54.13M |
| Net Receivables | $318.00K | $298.00K | $484.00K | $623.00K | $772.00K |
| Inventory | $- | $- | $-12.24M | $-34.24M | $- |
| Other Current Assets | $12.04M | $9.45M | $13.49M | $25.99M | $5.18M |
| Total Current Assets | $125.95M | $128.86M | $231.55M | $205.03M | $57.49M |
| Property Plant Equipment Net | $1.01M | $1.62M | $1.10M | $1.33M | $1.65M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $269.00K | $6.97M | $7.05M | $7.12M |
| Goodwill and Intangible Assets | $- | $269.00K | $6.97M | $7.05M | $7.12M |
| Long Term Investments | $- | $62.77M | $12.24M | $34.24M | $- |
| Tax Assets | $- | $- | $3.36M | $- | $- |
| Other Non-Current Assets | $93.37M | $3.89M | $-630.00K | $3.55M | $4.51M |
| Total Non-Current Assets | $94.38M | $68.55M | $23.05M | $46.18M | $13.29M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $220.33M | $197.41M | $254.60M | $251.21M | $70.78M |
| Account Payables | $4.69M | $8.88M | $10.35M | $9.98M | $5.25M |
| Short Term Debt | $- | $426.00K | $1.37M | $1.39M | $1.21M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $3.89M | $- | $- | $10.05M | $5.91M |
| Other Current Liabilities | $23.02M | $21.65M | $10.22M | $11.56M | $8.41M |
| Total Current Liabilities | $31.60M | $30.95M | $21.94M | $22.93M | $14.87M |
| Long Term Debt | $- | $- | $- | $- | $10.65M |
| Deferred Revenue Non-Current | $- | $- | $-1.57M | $-2.17M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $367.00K | $367.00K | $367.00K |
| Other Non-Current Liabilities | $33.18M | $9.27M | $34.67M | $30.57M | $7.24M |
| Total Non-Current Liabilities | $33.18M | $9.27M | $35.04M | $30.94M | $18.26M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $64.77M | $40.23M | $56.98M | $53.87M | $33.13M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $- |
| Retained Earnings | $-902.86M | $-770.80M | $-682.32M | $-595.41M | $-504.54M |
| Accumulated Other Comprehensive Income Loss | $97.00K | $-106.00K | $-897.00K | $-224.00K | $-94.00K |
| Other Total Stockholders Equity | $1.06B | $928.08M | $880.83M | $792.97M | $542.29M |
| Total Stockholders Equity | $155.55M | $157.18M | $197.62M | $197.34M | $37.65M |
| Total Equity | $155.55M | $157.18M | $197.62M | $197.34M | $37.65M |
| Total Liabilities and Stockholders Equity | $220.33M | $197.41M | $254.60M | $251.21M | $70.78M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $220.33M | $197.41M | $254.60M | $251.21M | $70.78M |
| Total Investments | $89.02M | $142.00M | $184.54M | $198.31M | $32.07M |
| Total Debt | $- | $426.00K | $684.00K | $693.00K | $11.26M |
| Net Debt | $-24.57M | $-39.45M | $-44.59M | $-26.66M | $-42.88M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $24.57M | $47.65M | $22.83M | $35.84M | $39.88M | $39.04M | $31.15M | $44.72M | $45.28M | $61.65M | $68.26M | $36.34M | $27.35M | $53.60M | $113.45M | $35.27M | $54.13M | $23.64M | $32.59M | $53.99M |
| Short Term Investments | $89.02M | $80.07M | $88.26M | $92.33M | $79.23M | $64.01M | $88.62M | $126.08M | $172.29M | $186.41M | $180.34M | $143.28M | $164.06M | $144.28M | $118.23M | $93.03M | $32.07M | $29.83M | $35.53M | $25.01M |
| Cash and Short Term Investments | $113.59M | $127.72M | $111.09M | $128.17M | $119.11M | $187.00M | $210.77M | $204.41M | $229.81M | $248.06M | $248.60M | $179.62M | $225.66M | $197.88M | $231.67M | $128.29M | $54.13M | $55.23M | $68.11M | $79.00M |
| Net Receivables | $318.00K | $343.00K | $325.00K | $373.00K | $298.00K | $346.00K | $431.00K | $686.00K | $484.00K | $597.00K | $637.00K | $633.00K | $623.00K | $811.00K | $939.00K | $817.00K | $772.00K | $887.00K | $775.00K | $933.00K |
| Inventory | $- | $- | $- | $1 | $- | $-83.94M | $-90.99M | $-33.60M | $-12.24M | $- | $- | $1 | $-34.24M | $- | $1 | $1 | $- | $1 | $1 | $- |
| Other Current Assets | $12.04M | $4.26M | $6.22M | $6.80M | $9.45M | $19.67M | $12.73M | $12.87M | $13.49M | $7.91M | $10.11M | $21.25M | $25.99M | $14.18M | $17.30M | $10.78M | $5.18M | $3.63M | $4.13M | $5.55M |
| Total Current Assets | $125.95M | $132.33M | $117.64M | $135.34M | $128.86M | $123.07M | $132.94M | $184.36M | $231.55M | $256.57M | $259.35M | $190.88M | $205.03M | $205.78M | $241.26M | $134.50M | $57.49M | $58.00M | $70.95M | $82.71M |
| Property Plant Equipment Net | $1.01M | $1.13M | $4.40M | $5.25M | $1.62M | $1.76M | $1.90M | $1.51M | $1.10M | $1.15M | $1.28M | $1.28M | $1.33M | $1.17M | $1.29M | $1.42M | $1.65M | $1.92M | $2.23M | $2.19M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $269.00K | $6.92M | $6.93M | $6.95M | $6.97M | $6.99M | $7.01M | $7.03M | $7.05M | $7.07M | $7.09M | $7.11M | $7.12M | $7.14M | $7.16M | $7.18M |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $269.00K | $6.92M | $6.93M | $6.95M | $6.97M | $6.99M | $7.01M | $7.03M | $7.05M | $7.07M | $7.09M | $7.11M | $7.12M | $7.14M | $7.16M | $7.18M |
| Long Term Investments | $90.30M | $- | $38.78M | $33.20M | $62.77M | $83.94M | $90.99M | $33.60M | $12.24M | $- | $7.22M | $23.95M | $34.24M | $45.73M | $34.50M | $14.36M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $2.15M | $- | $- | $- | $3.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.07M | $48.93M | $262.00K | $281.00K | $1.74M | $2.66M | $2.89M | $3.27M | $-630.00K | $2.92M | $3.11M | $3.38M | $3.55M | $3.74M | $3.91M | $4.01M | $4.51M | $4.84M | $4.65M | $4.73M |
| Total Non-Current Assets | $94.38M | $50.06M | $43.44M | $38.73M | $68.55M | $95.29M | $102.71M | $45.34M | $23.05M | $11.06M | $18.62M | $35.65M | $46.18M | $57.71M | $46.78M | $26.90M | $13.29M | $13.90M | $14.04M | $14.10M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $220.33M | $182.39M | $161.07M | $174.06M | $197.41M | $218.35M | $235.65M | $229.71M | $254.60M | $267.63M | $277.98M | $226.53M | $251.21M | $263.49M | $288.05M | $161.40M | $70.78M | $71.90M | $85.00M | $96.81M |
| Account Payables | $4.69M | $7.66M | $7.27M | $10.81M | $8.88M | $9.65M | $11.43M | $8.19M | $10.35M | $7.67M | $5.70M | $8.12M | $9.98M | $7.56M | $4.24M | $7.29M | $5.25M | $5.08M | $5.50M | $6.95M |
| Short Term Debt | $- | $- | $- | $- | $852.00K | $620.00K | $916.00K | $1.21M | $1.37M | $1.53M | $1.48M | $1.43M | $1.39M | $1.34M | $1.29M | $1.25M | $1.21M | $1.18M | $1.22M | $1.25M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $3.89M | $3.77M | $- | $- | $19.45M | $15.16M | $8.74M | $- | $- | $- | $- | $- | $10.05M | $7.41M | $6.93M | $3.60M | $5.91M | $3.82M | $9.34M | $10.37M |
| Other Current Liabilities | $23.02M | $7.39M | $8.41M | $9.27M | $21.22M | $17.05M | $10.49M | $8.86M | $10.22M | $10.59M | $9.03M | $7.17M | $11.56M | $8.94M | $9.38M | $5.96M | $8.41M | $6.53M | $11.02M | $12.41M |
| Total Current Liabilities | $31.60M | $18.82M | $15.68M | $20.08M | $30.95M | $27.32M | $22.83M | $18.26M | $21.94M | $19.79M | $16.22M | $16.73M | $22.93M | $17.84M | $14.92M | $14.51M | $14.87M | $12.79M | $17.75M | $20.60M |
| Long Term Debt | $- | $- | $2.37M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.73M | $10.69M | $10.65M | $10.61M | $10.57M | $10.57M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $-3.07M | $-1.83M | $-1.90M | $-1.97M | $-1.57M | $-1.62M | $-1.82M | $-2.02M | $-2.17M | $-2.38M | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $2.15M | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $367.00K | $549.00K | $549.00K | $549.00K |
| Other Non-Current Liabilities | $33.18M | $33.43M | $9.20M | $11.97M | $9.27M | $34.33M | $32.70M | $34.27M | $34.67M | $27.64M | $25.64M | $29.23M | $30.57M | $28.71M | $28.22M | $23.54M | $7.24M | $7.20M | $6.77M | $6.91M |
| Total Non-Current Liabilities | $33.18M | $33.43M | $11.57M | $11.97M | $9.27M | $34.70M | $33.07M | $34.64M | $35.04M | $28.00M | $26.01M | $29.60M | $30.94M | $29.07M | $39.31M | $34.60M | $18.26M | $18.36M | $17.89M | $18.03M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $64.77M | $52.24M | $27.25M | $32.05M | $40.23M | $62.02M | $55.90M | $52.90M | $56.98M | $47.79M | $42.22M | $46.33M | $53.87M | $46.91M | $54.23M | $49.10M | $33.13M | $31.14M | $35.63M | $38.64M |
| Preferred Stock | $- | $- | $- | $- | $71.67B | $- | $- | $- | $- | $- | $- | $- | $595.41M | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $1.00K | $- | $- | $- | $- | $- |
| Retained Earnings | $-902.86M | $-806.31M | $-798.72M | $-787.74M | $-770.80M | $-769.30M | $-740.04M | $-710.48M | $-682.32M | $-654.68M | $-634.73M | $-614.20M | $-595.41M | $-572.60M | $-551.46M | $-533.30M | $-504.54M | $-491.37M | $-480.71M | $-469.11M |
| Accumulated Other Comprehensive Income Loss | $97.00K | $427.00K | $-463.00K | $-364.00K | $-106.00K | $-1.13M | $-1.11M | $-354.00K | $-897.00K | $-1.47M | $-1.33M | $-972.00K | $-224.00K | $-3.00K | $-184.00K | $-140.00K | $-94.00K | $-44.00K | $15.00K | $47.00K |
| Other Total Stockholders Equity | $1.06B | $936.03M | $933.01M | $930.11M | $928.08M | $926.77M | $920.90M | $887.64M | $880.83M | $875.98M | $871.80M | $795.37M | $792.97M | $789.19M | $785.46M | $645.73M | $542.29M | $532.17M | $530.06M | $527.24M |
| Total Stockholders Equity | $155.55M | $130.15M | $133.82M | $142.01M | $157.18M | $156.33M | $179.75M | $176.81M | $197.62M | $219.84M | $235.75M | $180.20M | $197.34M | $216.58M | $233.81M | $112.29M | $37.65M | $40.76M | $49.37M | $58.17M |
| Total Equity | $155.55M | $130.15M | $133.82M | $142.01M | $157.18M | $156.33M | $179.75M | $176.81M | $197.62M | $219.84M | $235.75M | $180.20M | $197.34M | $216.58M | $233.81M | $112.29M | $37.65M | $40.76M | $49.37M | $58.17M |
| Total Liabilities and Stockholders Equity | $220.33M | $182.39M | $161.07M | $174.06M | $197.41M | $218.35M | $235.65M | $229.71M | $254.60M | $267.63M | $277.98M | $226.53M | $251.21M | $263.49M | $288.05M | $161.40M | $70.78M | $71.90M | $85.00M | $96.81M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $220.33M | $182.39M | $161.07M | $174.06M | $197.41M | $218.35M | $235.65M | $229.71M | $254.60M | $267.63M | $277.98M | $226.53M | $251.21M | $263.49M | $288.05M | $161.40M | $70.78M | $71.90M | $85.00M | $96.81M |
| Total Investments | $179.33M | $80.07M | $127.04M | $125.52M | $181.88M | $64.01M | $88.62M | $159.68M | $184.54M | $186.41M | $187.56M | $167.24M | $198.31M | $190.01M | $152.73M | $107.39M | $32.07M | $29.83M | $35.53M | $25.01M |
| Total Debt | $- | $- | $2.82M | $3.47M | $426.00K | $310.00K | $458.00K | $603.00K | $684.00K | $766.00K | $741.00K | $716.00K | $693.00K | $669.00K | $11.38M | $11.32M | $11.26M | $11.20M | $11.18M | $11.20M |
| Net Debt | $-24.57M | $-47.65M | $-20.02M | $-32.37M | $-39.45M | $-38.73M | $-30.69M | $-44.12M | $-44.59M | $-60.89M | $-67.52M | $-35.63M | $-26.66M | $-52.93M | $-102.07M | $-23.95M | $-42.88M | $-12.44M | $-21.40M | $-42.80M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-132.06M | $-88.48M | $-86.91M | $-90.86M | $-51.02M |
| Depreciation and Amortization | $807.00K | $863.00K | $797.00K | $923.00K | $1.32M |
| Deferred Income Tax | $- | $-367.00K | $- | $752.00K | $-182.00K |
| Stock Based Compensation | $10.86M | $20.54M | $15.04M | $14.06M | $11.21M |
| Change in Working Capital | $10.92M | $9.39M | $-1.20M | $-1.34M | $-2.36M |
| Accounts Receivables | $-20.00K | $186.00K | $139.00K | $149.00K | $4.90M |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-4.19M | $-1.47M | $368.00K | $3.65M | $-5.22M |
| Other Working Capital | $15.13M | $10.68M | $-1.70M | $-5.15M | $-2.04M |
| Other Non Cash Items | $89.41M | $-20.27M | $4.70M | $24.34M | $2.39M |
| Net Cash Provided by Operating Activities | $-20.07M | $-78.33M | $-67.57M | $-52.13M | $-38.63M |
| Investments in Property Plant and Equipment | $-121.00K | $-1.31M | $-605.00K | $-308.00K | $-453.00K |
| Acquisitions Net | $- | $- | $-13.23M | $167.32M | $-6.84M |
| Purchases of Investments | $-119.98M | $-135.68M | $-164.75M | $-235.15M | $-47.71M |
| Sales Maturities of Investments | $86.14M | $183.20M | $177.99M | $67.83M | $54.55M |
| Other Investing Activities | $-35.81M | $- | $13.23M | $-167.32M | $6.84M |
| Net Cash Used for Investing Activities | $-69.77M | $46.22M | $12.63M | $-167.63M | $6.39M |
| Debt Repayment | $- | $- | $- | $-11.48M | $10.78M |
| Common Stock Issued | $74.91M | $26.71M | $72.74M | $238.20M | $7.74M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-377.00K | $86.00K | $123.00K | $-1.67M | $7.60M |
| Net Cash Used Provided by Financing Activities | $74.54M | $26.71M | $72.87M | $225.05M | $18.37M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-15.31M | $-5.40M | $17.93M | $5.29M | $-13.87M |
| Cash at End of Period | $24.57M | $39.88M | $45.28M | $27.35M | $22.06M |
| Cash at Beginning of Period | $39.88M | $45.28M | $27.35M | $22.06M | $35.94M |
| Operating Cash Flow | $-20.07M | $-78.33M | $-67.57M | $-52.13M | $-38.63M |
| Capital Expenditure | $-121.00K | $-1.31M | $-605.00K | $-308.00K | $-453.00K |
| Free Cash Flow | $-20.20M | $-79.63M | $-68.17M | $-52.44M | $-39.09M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-96.55M | $-7.59M | $-10.99M | $-16.94M | $-1.49M | $-29.26M | $-29.57M | $-28.16M | $-27.64M | $-19.95M | $-20.53M | $-18.79M | $-22.80M | $-21.15M | $-18.16M | $-28.75M | $-13.17M | $-10.66M | $-11.60M | $-15.59M |
| Depreciation and Amortization | $143.00K | $221.00K | $200.00K | $243.00K | $228.00K | $219.00K | $218.00K | $198.00K | $190.00K | $193.00K | $206.00K | $208.00K | $197.00K | $191.00K | $247.00K | $288.00K | $-449.00K | $591.00K | $606.00K | $576.00K |
| Deferred Income Tax | $- | $- | $- | $- | $6.26M | $-635.00K | $198.00K | $- | $- | $- | $- | $- | $- | $752.00K | $- | $- | $-182.00K | $- | $- | $- |
| Stock Based Compensation | $2.86M | $3.00M | $2.90M | $2.09M | $1.27M | $5.95M | $6.52M | $6.81M | $4.81M | $4.19M | $3.69M | $2.35M | $3.85M | $3.70M | $3.83M | $2.67M | $2.50M | $1.94M | $3.31M | $3.45M |
| Change in Working Capital | $-11.92M | $25.60M | $-4.68M | $-9.01M | $13.27M | $-3.16M | $3.67M | $-4.40M | $-3.58M | $5.55M | $368.00K | $-3.53M | $-519.00K | $5.00M | $-2.94M | $-2.88M | $2.44M | $-4.65M | $-3.14M | $2.98M |
| Accounts Receivables | $25.00K | $-18.00K | $48.00K | $-75.00K | $48.00K | $85.00K | $255.00K | $-202.00K | $113.00K | $40.00K | $-4.00K | $-10.00K | $188.00K | $128.00K | $-122.00K | $-45.00K | $115.00K | $-112.00K | $158.00K | $4.74M |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-124.67M | $-40.52M | $-50.32M | $-54.80M | $-59.55M |
| Accounts Payables | $-2.97M | $393.00K | $-3.54M | $1.93M | $-394.00K | $-2.15M | $3.23M | $-2.16M | $2.69M | $1.96M | $-2.42M | $-1.86M | $2.36M | $2.58M | $-3.13M | $1.84M | $229.00K | $578.00K | $-1.71M | $-4.32M |
| Other Working Capital | $-8.97M | $25.23M | $-1.19M | $-10.86M | $13.62M | $-1.09M | $185.00K | $-2.03M | $-6.38M | $3.55M | $2.79M | $-1.66M | $-3.07M | $2.28M | $315.00K | $120.00M | $42.62M | $45.21M | $53.21M | $62.11M |
| Other Non Cash Items | $96.53M | $758.00K | $7.04M | $3.52M | $-26.30M | $2.33M | $-1.70M | $-800.00K | $7.10M | $2.20M | $-3.40M | $-1.20M | $2.20M | $900.00K | $4.80M | $16.44M | $47.00K | $626.00K | $-1.71M | $1.77M |
| Net Cash Provided by Operating Activities | $-8.94M | $22.00M | $-12.32M | $-20.82M | $-6.76M | $-24.56M | $-20.65M | $-26.35M | $-19.11M | $-7.82M | $-19.67M | $-20.97M | $-17.07M | $-10.61M | $-12.22M | $-12.23M | $-8.86M | $-12.15M | $-10.82M | $-6.80M |
| Investments in Property Plant and Equipment | $- | $- | $14.00K | $-135.00K | $-441.00K | $-84.00K | $-231.00K | $-553.00K | $-105.00K | $-150.00K | $-186.00K | $-164.00K | $-200.00K | $-56.00K | $-52.00K | $- | $-8.00K | $-304.00K | $-17.00K | $-124.00K |
| Acquisitions Net | $- | $- | $- | $- | $39.54M | $-32.62M | $19.43M | $-26.35M | $-2.81M | $-1.37M | $21.04M | $- | $-52.00K | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-70.43M | $-14.34M | $-35.22M | $- | $- | $-17.16M | $-89.99M | $-28.52M | $-46.02M | $-33.63M | $-70.54M | $-14.56M | $-35.29M | $-52.57M | $-61.48M | $-85.81M | $-7.82M | $-12.76M | $-18.27M | $-8.87M |
| Sales Maturities of Investments | $17.51M | $17.13M | $34.53M | $16.97M | $7.99M | $49.78M | $70.56M | $54.88M | $48.83M | $35.00M | $49.50M | $44.65M | $26.32M | $14.96M | $16.06M | $10.50M | $5.52M | $18.30M | $7.80M | $22.93M |
| Other Investing Activities | $-35.81M | $- | $-688.00K | $16.97M | $7.99M | $32.62M | $-19.43M | $26.35M | $2.81M | $1.37M | $-21.04M | $30.10M | $52.00K | $-37.62M | $-45.42M | $-75.31M | $-2.30M | $5.54M | $-10.47M | $14.07M |
| Net Cash Used for Investing Activities | $-88.72M | $2.79M | $-674.00K | $16.83M | $7.55M | $32.53M | $-19.66M | $25.80M | $2.70M | $1.22M | $-21.22M | $29.93M | $-9.18M | $-37.67M | $-45.47M | $-75.31M | $-2.31M | $5.24M | $-10.49M | $13.94M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-11.48M | $- | $- | $-9.00K | $-36.00K | $-72.00K | $10.89M |
| Common Stock Issued | $74.91M | $- | $- | $- | $49.00K | $15.00K | $26.74M | $- | $37.00K | $- | $72.74M | $37.00K | $-238.20M | $- | $134.85M | $103.35M | $45.00K | $- | $- | $25.00K |
| Common Stock Repurchased | $- | $66.00K | $-11.00K | $-55.00K | $102.00K | $-102.00K | $- | $- | $- | $-11.00K | $- | $-7.00K | $-2.00K | $-84.00K | $- | $- | $7.74M | $- | $-25.00K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-25.00K | $- | $- | $- |
| Other Financing Activities | $-333.00K | $22.00K | $-11.00K | $-55.00K | $49.00K | $-87.00K | $26.74M | $- | $37.00K | $-11.00K | $67.00K | $30.00K | $-2.00K | $- | $1.02M | $-2.60M | $7.84M | $-242.00K | $-25.00K | $25.00K |
| Net Cash Used Provided by Financing Activities | $74.58M | $22.00K | $-11.00K | $-55.00K | $49.00K | $-87.00K | $26.74M | $- | $37.00K | $-11.00K | $72.81M | $30.00K | $-2.00K | $-11.57M | $135.87M | $100.75M | $7.83M | $-278.00K | $-97.00K | $10.92M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-17.07M | $- | $17.07M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-23.08M | $24.82M | $-13.01M | $-4.04M | $838.00K | $7.89M | $-13.57M | $-555.00K | $-16.38M | $-6.61M | $31.92M | $8.99M | $-26.25M | $-59.84M | $78.18M | $13.20M | $-3.33M | $-7.19M | $-21.41M | $18.05M |
| Cash at End of Period | $24.57M | $47.65M | $22.83M | $35.84M | $39.88M | $39.04M | $31.15M | $44.72M | $45.28M | $61.65M | $68.26M | $36.34M | $27.35M | $53.60M | $113.45M | $35.27M | $22.06M | $25.40M | $32.59M | $53.99M |
| Cash at Beginning of Period | $47.65M | $22.83M | $35.84M | $39.88M | $39.04M | $31.15M | $44.72M | $45.28M | $61.65M | $68.26M | $36.34M | $27.35M | $53.60M | $113.45M | $35.27M | $22.06M | $25.40M | $32.59M | $53.99M | $35.94M |
| Operating Cash Flow | $-8.94M | $22.00M | $-12.32M | $-20.82M | $-6.76M | $-24.56M | $-20.65M | $-26.35M | $-19.11M | $-7.82M | $-19.67M | $-20.97M | $-17.07M | $-10.61M | $-12.22M | $-12.23M | $-8.86M | $-12.15M | $-10.82M | $-6.80M |
| Capital Expenditure | $-35.81M | $- | $14.00K | $-135.00K | $-441.00K | $-84.00K | $-231.00K | $-553.00K | $-105.00K | $-150.00K | $-186.00K | $-164.00K | $-200.00K | $-56.00K | $-52.00K | $- | $-8.00K | $-304.00K | $-17.00K | $-124.00K |
| Free Cash Flow | $-44.75M | $22.00M | $-12.31M | $-20.95M | $-7.20M | $-24.64M | $-20.89M | $-26.91M | $-19.22M | $-7.97M | $-19.85M | $-21.13M | $-17.27M | $-10.66M | $-12.27M | $-12.23M | $-8.87M | $-12.45M | $-10.84M | $-6.93M |
Aclaris Therapeutics Dividends
Explore Aclaris Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Aclaris Therapeutics News
Read the latest news about Aclaris Therapeutics, including recent articles, headlines, and updates.
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Leerink Partners Global Healthcare Conference in Miami, Florida.
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the unique properties of Aclaris Therapeutics' ATI-2138, a novel investigational covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3) in development for the treatment of autoimmune and inflammatory diseases.
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board (SAB), which initially includes experts in the field of pulmonology. These include Marianne Mann, M.D.
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective January 2, 2025, the Compensation Committee of Aclaris' Board of Directors (the Committee) granted nonstatutory stock options to purchase an aggregate of 215,000 shares of its common stock and 61,000 restricted stock units to 1 new employee under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the new employee becoming an employee of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York. A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris' website, www.aclaristx.com.
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
On Monday, Aclaris Therapeutics, Inc. ACRS entered into an exclusive license agreement with Biosion Inc for worldwide rights (excluding Greater China) to BSI-045B and BSI-502, a preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R.
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single digit sales royalty Aclaris Therapeutics will be responsible for development and commercialization of BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R worldwide (excluding Greater China) NEWARK, Del. and NANJING, China , Nov. 18, 2024 /PRNewswire/ -- Biosion, Inc. (Biosion), a global R&D stage biotechnology company, today announced that it has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding Greater China) to BSI-045B, a potential First-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R.
Aclaris Therapeutics Announces $80 Million Private Placement
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. The private placement is expected to close on or about November 19, 2024, subject to the satisfaction of customary closing conditions.
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
- Enhances Aclaris' pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York.
AllClear Repair Services Approved as Honeywell Authorized Service Center
MIRAMAR, Fla.--(BUSINESS WIRE)-- #defenseaerospace--AllClear Repair Services (“ACRS”), a wholly owned subsidiary of AllClear Aerospace & Defense (“AllClear”), has been approved by Honeywell as an authorized service center for Honeywell military APUs and mechanical components for C-130, F-15, F-16, F-18 and military derivatives of B707 platforms. The Honeywell authorized service center agreement authorizes ACRS to perform maintenance on pneumatic components, starter control valves, anti-ice valves, wheels and b.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris' future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales of OLUMIANT® (baricitinib) for the treatment of alopecia areata to OMERS, one of Canada's largest defined benefit pension plans.
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.
Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)
Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major rheumatoid arthritis markets reached a value of US$ 27.5 billion in 2023. Looking forward, the 7MM are projected to reach US$ 33.8 billion by 2034, exhibiting a growth rate (CAGR) of 2.32% during 2023-2034.
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida. A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris' website, www.aclaristx.com.
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Aclaris Therapeutics, Inc. (NASDAQ:ACRS ) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET Company Participants Kevin Balthaser - Chief Financial Officer Neal Walker - Interim Chief Executive Officer Joe Monahan - Chief Scientific Officer Wally Smith - Scientific & Business Development Consultant Conference Call Participants Roger Song - Jefferies Thomas Smith - Leerink Partners Corinne Jenkins - Goldman Sachs Julian Harrison - Big TIG Alex Thompson - Stifel Gavin Clark-Gartner - Evercore ISI Operator Good day, and thank you for standing by. Welcome to the Aclaris Therapeutics First Quarter 2024 Conference Call.
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update.
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
CAMBRIDGE, Mass. , April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ACRS.